Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology|May 22, 2026
The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trialMan-Fung Yuen, Edward Gane, Jacinta A Holmes, et al.
Hepatology International|August 24, 2021
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapyGeorge Lau, Ming-Lung Yu, Grace Wong, et al.
Cancers|December 23, 2023
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie Ngu, et al.
Cancers|June 19, 2024
Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
The New England Journal of Medicine|August 18, 2016
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisFrederik Nevens, Pietro Andreone, Giuseppe Mazzella, et al.
Cancers|September 14, 2024
Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Hepatology Communications|April 1, 2026
The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensusAvik Majumdar, Jacinta Holmes, Stuart K Roberts, et al.
Pageof 15